Pipeline
ATA3219
Atara is developing an off-the-shelf, allogeneic CAR T immunotherapy targeting CD19 (ATA3219) using its next generation technologies and EBV T cell platform.
ATA3219
| Program/Indication | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|
| ATA3219: B-cell malignancies | ||||
|
||||
| Program/Indication | Phase | |
|---|---|---|
| ATA3219: B-cell malignancies | Preclinical | |
|
||
Next-Generation CAR T Technology
Our preclinical pipeline is rapidly expanding with novel technologies and next-generation, multi-targeted CAR T immunotherapies thanks to our collaborations with Moffitt Cancer Center and Memorial Sloan Kettering Cancer Center.
View Next-Generation CAR T
Patients
At Atara, we recognize that some patients with serious, life-threatening diseases may not have access to some clinical studies or satisfactory treatment alternatives. That is why we are committed to making every effort to support patients in need of treatment options.
Medical Professionals
We have designed our clinical studies to evaluate the potential of our investigational treatments in a well-defined cohort of patients with eligibility criteria that allow for appropriate assessment of safety and clinical effect. If you are interested in learning more about our ongoing clinical studies, please contact us at ClinicalStudies@atarabio.com.